MedTrace Logo

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

NCT00186940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2017-04-25

No results posted yet for this study

Summary

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Conditions

Interventions

DRUG

Rasburicase

Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.

Sponsors & Collaborators

Principal Investigators

  • Raul C. Ribeiro, MD · St. Jude Children's Research Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00186940 on ClinicalTrials.gov